Prospective Follow-up After MVA-BN Booster Vaccination
NCT07342829 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 95
Last updated 2026-01-20
Summary
POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.
Conditions
- Monkeypox (Mpox)
Sponsors & Collaborators
-
Institute of Tropical Medicine, Belgium
lead OTHER
Principal Investigators
-
Laurens Liesenborghs, MD · Institute of Tropical Medicine Antwerp
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-15
- Primary Completion
- 2028-06-30
- Completion
- 2028-06-30
Countries
- Belgium
Study Locations
More Related Trials
-
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
NCT06771479 ·Status: RECRUITING ·Phase: PHASE1
-
Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study
NCT05562323 ·Status: RECRUITING
-
Cohort Study of Healthcare Workers Receiving Imvanex®
NCT03745131 ·Status: COMPLETED
-
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
NCT05512949 ·Status: COMPLETED ·Phase: PHASE2
-
MVA Post-Event: Administration Timing and Boost Study
NCT00437021 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines
NCT05988203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care Only
NCT06721585 ·Status: COMPLETED
-
A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects
NCT00316524 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
NCT07093489 ·Status: NOT_YET_RECRUITING
-
Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects
NCT00189943 ·Status: COMPLETED ·Phase: PHASE1
-
Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial
NCT03699124 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects
NCT00565929 ·Status: COMPLETED ·Phase: PHASE1
-
Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCT
NCT05745987 ·Status: RECRUITING ·Phase: PHASE4
-
JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo
NCT02977715 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy/Effectiveness, Safety, and Immunogenicity of LC16m8 Mpox Vaccine in Colombia
NCT06223919 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluating the Human Immune Response to the JYNNEOS Vaccine
NCT06366672 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
NCT00189956 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders
NCT00189917 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Study With MVA BN and Dryvax
NCT00082446 ·Status: COMPLETED ·Phase: PHASE1
-
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
NCT07199569 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®
NCT01913353 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).
NCT00430534 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)
NCT03349983 ·Status: COMPLETED ·Phase: PHASE1
-
High Dose IMVAMUNE® in Vaccinia-Naive Individuals
NCT00879762 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
NCT00316602 ·Status: COMPLETED ·Phase: PHASE2